Cerebral malaria or other CNS infection Infections and Infestations Plasmodium falciparum malaria with cerebral complications
Conditions
Interventions
This is a follow up study to assess the effects of malaria on brain function. No intervention is anticipated.
Sponsors
Mahidol Oxford Tropical Medicine Research Unit (MORU) (Thailand)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: TQQ+ questionnaire, socioeconomic status, clinical history, height on: 1. Surviving children originally enrolled in Study 13 2. Male or female 3. Written informed consent by legally acceptable representative (plus assent if appropriate) 4. Willingness and ability of the participants/guardians to comply with the study tests Detailed neurocognitive exams 1. ~30% stratified sample of the surviving study cohort meeting criteria above 2. TQQ positive children 3. >8 years of age (Additional inclusion criteria will apply for participants who undergo EEG and/or MRI)
Exclusion criteria
Exclusion criteria: TQQ+ 1. Signs of acute illness Detailed neurocognitive exams 1. Signs of acute illness 2. Anti-malarial injection at enrolment into Study 13 (Additional exclusion criteria will apply for participants who will undergo EEG and/or MRI)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To describe the long-term effects of cerebral malaria or other CNS infection in childhood on the prevalence of neurological deficit in a cohort re-visited 7-13 years later | — |
Secondary
| Measure | Time frame |
|---|---|
| Prevalence of neurocognitive disability 1. To compare prevalence of neurological and cognitive deficits by detailed neurocognitive exams, by status at recruitment (2000-06) 2. To compare prevalence of neurological and cognitive deficits by detailed neurocognitive exams, by treatment allocation at recruitment and, where possible, by time to reach a health facility (2000-06) 3. To compare prevalence of neurological and cognitive deficits by detailed neurocognitive exam, by status at follow-up (2013-14) 4. To quantify types of disability by each separate neurocognitive test Characterising neurological disability 1. To confirm and characterise the type of neurological damage by electro-encephalogram (EEG) 2. To confirm and characterise neurological damage by magnetic resonance imaging (MRI) Development of screening tools 1. Develop and validate core metrics and neuro-development and cognitive instruments to measure neurocognitive disability in participating sites 2. Map using GPS all study participants? houses | — |
Countries
Bangladesh, Ghana, Tanzania
Outcome results
None listed